This is quite encouraging...
==============
Tuesday June 25, 7:31 am Eastern Time
Press Release
SOURCE: Hypertension Diagnostics, Inc.
Hypertension Diagnostics Surpasses 100 CVProfilor(R) DO-2020 System Placements In U.S.
Physicians Using the CVProfilor(R) Comment on the Value the Technology Has In Their Practices
ST. PAUL, Minn., June 25 /PRNewswire-FirstCall/ --
Hypertension Diagnostics, Inc. (Nasdaq: HDII - News), announced today that its CVProfilor® DO-2020 System has been placed in more than 100 physicians' offices in 24 states throughout the United States. Physicians using the device have spoken positively about the added-value the CVProfilor® System provides in better assessing and managing their patients for cardiovascular disease.
"We are pleased and encouraged with the comments we are receiving from our physician customers regarding their use of the CVProfilor® System. Two physicians in particular, Dr. Stephen Zuckerman and Dr. Shivinder S. Deol, are using the CVProfilor® because they felt they needed more specific information relative to the health of their patients' arteries," said Greg H. Guettler, President of Hypertension Diagnostics, Inc.
Stephen Zuckerman, M.D., an Internal Medicine physician at Aspen Medical Group in Minneapolis, Minnesota, is currently using the CVProfilor® System to assist in decisions for his hypertensive and diabetic patients. "We have been relying on the blood pressure cuff as our sole decision criteria for treating patients who may or may not have hypertension and, therefore, may or may not need pharmacologic therapy," said Dr. Zuckerman. "The CVProfilor® System gives me additional confidence in situations where patients have variable blood pressure readings by providing more specific information on the health of their arteries. In addition, many diabetic patients do not have elevated blood pressure and the CVProfilor® System allows me to determine whether or not these patients actually have underlying blood vessel disease. When diabetics are treated with an ACE Inhibitor [Angiotensin Converting Enzyme Inhibitors are used to lower blood pressure], we use the CVProfilor® System to assess the effects of that therapy in terms of its impact on the stiffness of blood vessels," added Dr. Zuckerman.
"Prior to using the CVProfilor® System, we had only a limited understanding of how certain drugs affected blood vessel stiffness. Now we have added a new dimension to the effective management of patients. The blood pressure cuff alone often is not an accurate means for determining the health of my patients' arteries and for determining which patients should be treated for blood vessel disease pharmacologically. This is important to me and to my patients. Our goal is to correct vascular problems that in the long run will result in a decrease in vascular disease such as heart attacks and strokes. The CVProfilor® System brings us closer to understanding the true condition of our patients' blood vessel health and achieving this goal," added Dr. Zuckerman.
Dr. Shivinder S. Deol, a family practice physician specializing in diabetes at Fam Doc Enterprises in Bakersfield, California, incorporated the CVProfilor® System into his practice to obtain a measurement of endothelial function (the essential function of the blood vessel) which allows him to begin appropriate measures for cardiovascular therapy far earlier than with any other device available. "The CVProfilor® System provides an added dimension to a patient's cardiovascular assessment since it presents large and small artery elasticity indices -- actual numbers patients look at which gives them greater incentive to make lifestyle changes. This technology is appropriate for any age but appears most effective with young adults since they will benefit most from lifestyle changes. I test any age patient because everyone should know where they stand in terms of their arterial health and it is never too late to make a few changes in your life and see a positive impact," said Dr. Deol.
"The CVProfilor® System is a new technology and physicians should not be resistant to use it. Everything is a matter of change and we have to adapt and be willing to embrace new ideas. This is a great technology and I think more physicians should be using it," added Dr. Deol.
<abridged>
==============
biz.yahoo.com
This increased usage of the Profilor does not account for the growth of Profilor placement in Europe - where the Profilor was approved prior to FDA's imprimatur - and in Asia where the company has a presence. |
